Drug-induced movement disorders: A primer

U.S. Pharmacist

Volumn 32, Issue 11, 2007, Pages

  Chen, Jack J ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE PLUS PERPHENAZINE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; FERROUS SULFATE; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; METOCLOPRAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; PEMOLINE; PHENOTHIAZINE; PROCHLORPERAZINE; PROPRANOLOL; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID;

ABNORMAL BEHAVIOR; AKATHISIA; ANAMNESIS; ARTICLE; CHOREA; DAILY LIFE ACTIVITY; DIET SUPPLEMENTATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTERPERSONAL COMMUNICATION; IRON DEFICIENCY; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MYOCLONUS; PARKINSONISM; PREVALENCE; QUALITY OF LIFE; RISK FACTOR; SOCIAL STATUS; TARDIVE DYSKINESIA; TASK PERFORMANCE; TIC; TREMOR;

EID: 48249113769     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (40)

1. Gelenberg AJ, Jefferson JW. Lithium tremor. J Clin Psychiatry. 1995;56:283-287.
2. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32:692-698.
3. Weiner WJ, Sanchez-Ramos J. Movement disorders and dopamimetic stimulant drugs: In: Lang AE, Weiner WJ, eds. Drug-Induced Movement Disorders. Mount Kisco, NY: Futura Publishing Co.; 1992:315-337.
4. Vandel P, Bonin B, Leveque E, Sechter D, et al. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997;7: 207-212.
5. Vela L, Sfakianakis GN, Heros D, et al. Chorea and contraceptives: case report with pet study and review of the literature. Mov Disord. 2004;19:349-352.
6. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004;161:160-163.
7. Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83:525-532.
8. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59:69-75.
9. Baldassano CF, Truman CJ, Nierenberg A, et al. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry. 1996;37:122-124.
10. Sachdev P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull. 1995;21:451-461.
11. Kuloglu M, Atmaca M, Ustundag B, et al. Serum iron levels in schizophrenic patients with or without akathisia. Eur Neuropsychopharmacol. 2003;13:67-71.
12. Leong GB, Silva JA. Neuroleptic-induced akathisia and violence: a review. J Forensic Sci. 2003;48:187-189.
13. Gold R, Lenox RH. Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. J Clin Psychiatry. 1995; 56:476-483.
14. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol. 2001;21:612-615.
15. Zubenko GS, Lipinski JF, Cohen BM, et al. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res. 1984;11:143-149.
16. Vinson DR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med. 2004;26:265-270.
17. Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. Anticholinergics for neuroleptic-induced acute akathisia (Cochrane Review). In: The Cochrane Library Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
18. Lima AR, Soares-Weiser K, Bacaltchuk J, et al. Benzodiazepines for neuroleptic-induced acute akathisia (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
19. Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. Am J Psychiatry. 1960;117:152-153.
20. Woerner MG, Kane JM, Lieberman A et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol. 1991; 11:34-42.
21. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(suppl 9):21-24.
22. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
23. Guy W. Abnormal Involuntary Movements Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. Washington, DC: United States Government Printing Office; 1976:534-537.
24. Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry. 1989;154:523-528.
25. Polizos P, Engelhardt DM. Dyskinetic phenomena in children treated with psychotropic medications. Psychopharmacol Bull. 1978;14:65-68.
26. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65:696-701.
27. Schrader C, Peschel T, Petermeyer M, et al. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord. 2004;19:583-585.
28. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27:159-169.
29. van Harten PN, Hoek HW, Matroos GE, et al. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998;155:565-567.
30. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585-592.
31. Spina E, Sturiale V, Valvo S, et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol. 1993;8:21-24.
32. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32:1335-1346.
33. Ballerini M, Bellini S, Niccolai C, et al. Neuroleptic-induced dystonia: incidence and risk factors. Eur Psychiatry. 2002;17:366-368.
34. Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry. 1988;145:993-996.
35. Goff DC, Arana GW, Greenblatt DJ, et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol. 1991;11:106-112.
36. Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol. 987;7:164-166.
37. Dressler D, Oeljeschlager RO, Ruther E. Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov Disord. 1997;12:585-587.
38. Kupsch A, Kuehn A, Klaffke S, et al. Deep brain stimulation in dystonia. J Neurol. 2003;250(suppl 1):147-152.
39. Jamora D, Lim SH, Pan A, et al. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22:130-133.
40. Hriso E, Kuhn T, Masdeu JC, et al. Extrapyramidal symptoms due to dopamine-blocking agents in patients With AIDS encephalopathy. Am J Psychiatry. 1991;148:1558-1561.